Jugal Jaiswal,
- Student, Department of Biotechnology, IILM University Greater Noida, Uttar Pradesh, India
Abstract
Epidermolysis Bullosa is a group of uncommon genetic disorders that primarily affect the skin and mucous membranes. It is marked by severe skin fragility and the formation of blisters even after minor trauma. Traditionally, the focus of Epidermolysis Bullosa research has been on its dermatological manifestations, which include recurrent blistering, scarring, and the potential for infections due to the compromised skin barrier. However, recent advancements in Epidermolysis Bullosa research have shifted attention to its broader implications, particularly its potential link to certain types of cancer, with cervical cancer emerging as one of the most notable associations. Studies suggest that individuals with certain forms of Epidermolysis Bullosa, especially those with recessive dystrophic Epidermolysis Bullosa, may be at heightened risk for developing cancers, including cervical cancer. This increased susceptibility is thought to be due to chronic skin damage, prolonged inflammation, and the role of genetic mutations in Epidermolysis Bullosa that may contribute to an environment conducive to oncogenic processes. For instance, in recessive dystrophic Epidermolysis Bullosa, mutations in the collagen VII gene result in abnormal skin structures that could potentially trigger cellular pathways leading to malignancy. This article aims to investigate the mechanisms that contribute to the heightened risk of cervical cancer in individuals with Epidermolysis Bullosa. By examining the molecular pathways involved in Epidermolysis Bullosa and their intersection with carcinogenesis, it highlights how defective skin integrity and persistent tissue damage could contribute to the development of cervical cancer. Furthermore, the paper explores the risk factors specific to Epidermolysis Bullosa patients, emphasizing the need for regular cancer screenings and early detection in these vulnerable populations. Understanding these connections is essential for enhancing clinical care and creating preventive strategies for patients with Epidermolysis Bullosa.
Keywords: Epidermolysis Bullosa, genetic, collagen VII, cell, cervical cancer
[This article belongs to International Journal of Cell Biology and Cellular Functions ]
Jugal Jaiswal. Epidermolysis Bullosa and Its Role in Cervical Cancer: An Overview. International Journal of Cell Biology and Cellular Functions. 2024; 02(02):14-18.
Jugal Jaiswal. Epidermolysis Bullosa and Its Role in Cervical Cancer: An Overview. International Journal of Cell Biology and Cellular Functions. 2024; 02(02):14-18. Available from: https://journals.stmjournals.com/ijcbcf/article=2024/view=190844
References
1. Vieira AR. Basis of inheritance in humans. Monogr Oral Sci. 2021;30:1–19. doi: 10.1159/000520765.
2. du Rand A, Hunt JMT, Feisst V, Sheppard HM. Epidermolysis bullosa: a review of the tissue-engineered skin substitutes used to treat wounds. Mol Diagn Ther. 2022;26(6):627–643. doi: 10.1007/s40291-022-00613-2
3. Ahmed AR, Kalesinskas M, Kooper-Johnson S. Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype. Autoimmun Rev. 2023;22(10):103444.
4. Boeira VL, Souza ES, Rocha Bde O, Oliveira PD, Oliveira Mde F, Rêgo VR, et al. Inherited epidermolysis bullosa: clinical and therapeutic aspects. An Bras Dermatol. 2013;88(2):185–98. doi: 10.1590/S0365-05962013000200001
5. Holl J, Kowalewski C, Zimek Z, Fiedor P, Kaminski A, Oldak T, et al. Chronic diabetic wounds and their treatment with skin substitutes. Cells. 2021;10(3):655.
6. McCance DJ, et al. The role of HPV in cervical cancer: the importance of early detection and prevention. J Gynec Obstet. 2018;81(5):377–89.
7. Has C, Nyström A, Amir Hossein Saeidian, Bruckner-Tuderman L, Jouni Uitto. Epidermolysis bullosa: molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol. 2018;71–72:313–29.
8. Danescu S, Negrutiu M, Has C. Treatment of epidermolysis bullosa and future directions: a review. Dermatol Therapy. 2024;14(8):2059–75.
9. Bruckner-Tuderman L. Newer treatment modalities in epidermolysis bullosa. Ind Dermatol Online J. 2019;10(3):244–50. doi: 10.4103/idoj.IDOJ_287_18
10. Sait H, Srivastava S, Saxena D. Integrated management strategies for epidermolysis bullosa: current insights. Int J Gen Med. 2022;15:5133–44.
| Volume | 02 |
| Issue | 02 |
| Received | 30/11/2024 |
| Accepted | 05/12/2024 |
| Published | 26/12/2024 |
| Publication Time | 26 Days |
Login
PlumX Metrics